Background: Delayed renal function after transplantation is a strong predictor of long-term graft survival. As an increased expression of endothelin (ET) has been demonstrated during ischemia/reperfusion injury, we hypothesized that ET-A receptor blockade could improve the recovery of acute renal failure in a rat model of isogeneic kidney transplantation. Methods: Kidneys of Fisher (F344, RT11v1) rat donors flushed with cooled University of Wisconsin solution were transplanted into bilaterally nephrectomized Fisher rats. Recipient animals were treated orally either with vehicle or the selective ET-A receptor antagonist LU135252 (30 mg/kg/day p.o.) for 14 days. Unilaterally nephrectomized Fisher rats not subjected to ischemia served as controls. No immunosuppression was given. On days 2, 6 and 14, metabolic studies were performed to evaluate endogenous creatinine clearance, fractional sodium excretion, and urinary endothelin excretion. Kidneys were harvested at the end of the experiment for determination of renal ET content and immunohistochemical assessment. Results: Urinary ET excretion was increased in vehicle-treated isografts compared to uninephrectomized controls after 14 days. Treatment with LU135252 resulted in a significant improvement in creatinine clearance and fractional sodium excretion to the level of uninephrectomized rats after 14 days. Isografts treated with selective ET-A receptor blockade demonstrated a marked reduction in cell surface markers for macrophages/monocytes, T cells, MHC-II, and ICAM-1. Conclusion: Treatment with the selective ET-A receptor antagonist LU135252 accelerates recovery of renal function after isogeneic renal transplantation and attenuates cellular graft infiltration. This effect could have major implications for the treatment of patients undergoing renal transplantation, as an improved initial renal function may delay the onset of chronic allograft rejection.

Keywords:
Endothelin, Endothelin A receptor antagonist, Kidney transplantation, Acute renal failure, rats
1.
Naimark D, Cole E: Determinants of long-term renal allograft survival. Transplant Rev 1994;8:93–113.
2.
Terasaki PI, Koyama H, Cecka JM, Gjertson DW: The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994;57:1450–1454.
3.
Van Es A, Hermans J, Von Bockel JH, Persijn GG, Van Hooff JP, Degraeff J: Effect of warm ischemia time and HLA (A and B) matching on renal cadaveric graft survival and rejection episodes. Transplantation 1983;36:255–258.
4.
Paller MS, Hoidal JR, Ferris TF: Oxygen free radicals in ischaemic acute renal failure in the rat. J Clin Invest 1984;74:1156–1162.
5.
Kon V, Yoshioka T, Fogo A, Ichikawa I: Glomerular actions of endothelin in vivo. J Clin Invest 1989;83:1762–1767.
6.
Shibouta Y, Suzuki N, Shino A, Matsumoto H, Terashita ZI, Kondo K, Nishikawa K: Pathophysiological role of endothelin in acute renal failure. Life Sci 1990;46:1611–1618.
7.
Tomita K, Naruse M, Nakanishi T, Tomura S, Matsuda O, Ando K, Shichiri M, Hirata Y, Marumo F: Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989;321:1127.
8.
Nir A, Clavell AL, Heublein D, Aarhus LL, Burnett JC Jr: Acute hypoxia and endogenous renal endothelin. J Am Soc Nephrol 1994;4:1920–1924.
9.
Hughes AK, Stricklett PK, Padilla E, Kohan DE: Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int 1996;49:181–189.
10.
Wilhelm SM, Simonson MS, Robinson AV, Stowe NT, Schulak JA: Endothelin upregulation and localization following renal ischemia and reperfusion. Kidney Int 1999;55:1011–1018.
11.
Gellai M, Jugus M, Fletcher T, Dewolf R, Nambi P: Reversal of postischemic acute renal failure with a selective endothelin-A receptor antagonist in the rat. J Clin Invest 1994;93:900–906.
12.
Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein EH, Elliott JD, Brooks DP: Nonpeptide endothelin receptor antagonists. V. Prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther 1995;275:200–206.
13.
Birck R, Knoll T, Braun C, Kirchengast M, Münter K, van der Woude FJ, Rohmeiss P: Improvement of postischemic acute renal failure with the novel orally available highly selective endothelin A receptor antagonist LU135252 in the rat. J Cardiovasc Pharmacol 1998;32:80–86.
14.
Lee S: An improved technique of renal transplantation in the rat. Surgery 1967;61:771–773.
15.
Mouri T, Takahashi K, Sone M, Murakami O, Ohneda M, Itoi K, et al: Calcitonin gene-related peptide-like immunoreactivities in pheochromocytomas. Peptides 1989;10:201–204.
16.
Nambi P, Pullen M, Jugus M, Gellai M: Rat kidney endothelin receptors in ischemia-induced acute renal failure. J Pharmacol Exp Ther 1993;264:345–348.
17.
Lopez-Farre A, Gomez Garre D, Bernabeu F, Lopez Novoa JM: A role for endothelin in the maintenance of postischemic renal failure in the rat. J Physiol 1991;444:513–522.
18.
Mino N, Kobayashi M, Nakajima A, Amano H, Shimamoto K, Ishikawa K, Watanabe K, Nishikibe M, Yano M, Ikemoto F: Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur J Pharmacol 1992;221:77–83.
19.
Chan L, Chittinandana A, Shapiro JI, Shanley PF, Schrier RW: Effect of an endothelin-receptor antagonist on ischemic acute renal failure. Am J Physiol 1994;266:F135–F138.
20.
Benigni A, Perico N, Ladny JR, Imberti O, Bellizzi L, Remuzzi G: Increased urinary excretion of endothelin-1 and its precursor, big-endothelin-1, in rats chronically treated with cyclosporine. Transplantation 1991;52:175–177.
21.
Brooks DP, Contino LC, Storer B, Ohlstein EH: Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol 1991;104:987–989.
22.
Büyükgebiz O, Aktan AÖ, Haklar G, Yalcin AS, Yegen C, Yalin R, Ercan ZS: BQ-123, a specific endothelin (ETA) receptor antagonist, prevents ischemia-reperfusion injury in kidney transplantation. Transpl Int 1996;9:201–207.
23.
King JM, Srivatava KD, Stefano GB, Bilfinger TV, Bahou WF, Magazine HI: Human monocyte adhesion is modulated by endothelin B receptor-coupled nitric oxide release. J Immunol 1997;158:880–886.
24.
Cunningham ME, Huribal M, Bala RJ, McMillen MA: Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit Care Med 1997;25:958–964.
25.
Azuma H, Nadeau KC, Ishibashi M, Tilney NL: Prevention of functional, structural, and molecular changes of chronic rejection of rat renal allografts by a specific macrophage inhibitor. Transplantation 1995;12:1577–1582.
26.
Orth SR, Odoni G, Amann K, Strelczyk P, Raschack M, Ritz E: ET(A) receptor blocker LU135252 prevents chronic transplant nephropathy in the ‘Fischer to Lewis’ model. J Am Soc Nephrol 1999;10:387–391.
27.
Braun C, Conzelmann T, Vetter S, Schaub M, Back WE, Kirchengast M, Yard B, Schnuelle P, van der Woude FJ, Rohmeiss P: Prevention of chronic renal allograft rejection in rats with the oral endothelin A-receptor antagonist LU135252. Transplantation 1999;68:739–746.
28.
Benigni A, Zoja C, Corna D, Orisio S, Facchinetti D, Benatti L, Remuzzi G: Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 1996;27:416–423.
29.
Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440–444.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.